Monthly Cost Comparison: Wegovy vs Mounjaro in the UK
Understanding Wegovy Compared to Mounjaro Monthly Costs
When evaluating Wegovy compared to Mounjaro for monthly expenses, the key difference lies in their distinct dose escalation schedules and maintenance pricing structures. Wegovy follows a structured 16-week escalation starting at £79.99 monthly for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), and £139.99 (1.7mg) before reaching the £209.99 maintenance dose at 2.4mg. This predictable monthly progression allows patients to budget effectively throughout their treatment journey. Mounjaro follows a different escalation pattern, making direct monthly cost comparisons more complex, though both medications represent significant long-term investments in weight management support.
The practical reality of Wegovy compared to Mounjaro monthly costs extends beyond the headline prices to include convenience factors and supply reliability. Wegovy's 6-week room temperature storage advantage over Mounjaro's 21-day limit can reduce replacement costs due to temperature exposure during travel or power outages. Both prescription-only medicines require ongoing monthly investment, but Wegovy's established pricing structure and bundle options through EverydayMeds provide clear cost predictability for patients planning their treatment budget over 12-24 months.
Wegovy Pricing Structure and Bundle Savings
EverydayMeds offers comprehensive Wegovy pricing with transparent monthly costs throughout the escalation phases. New customers benefit from code FIRST40 applied at checkout, bringing the starter 0.25mg dose to £79.99, whilst returning customers use code DOSE25 for continued competitive pricing. The Getting Started bundles like the Intro Duo (0.25mg & 0.5mg) at £169.99 provide two months of treatment in a single order, reducing delivery frequency and ensuring continuous supply. The Progress Duo (0.5mg & 1mg) at £189.99 covers weeks 5-12, whilst the Advance Duo (1mg & 1.7mg) at £269.99 bridges weeks 9-16 of the escalation protocol.
For maintenance phase planning, the Consistency 2.4mg bundle provides two pens at £419.99, whilst the Ultimate Stability Trio offers three months of 2.4mg maintenance supply for £649.99, ensuring uninterrupted treatment availability. Annual maintenance costs at 2.4mg calculate to approximately £2,520 when purchasing individual pens monthly, making bundle options attractive for patients committed to long-term weight management. The bundle approach reduces ordering frequency from monthly to quarterly, minimising administrative burden whilst maintaining the prescription-only medicine's clinical effectiveness through consistent supply.
Clinical Evidence: Wegovy Compared to Mounjaro Effectiveness
In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). The STEP programme demonstrated sustained weight management across multiple populations, with STEP 3 showing approximately clinically studied weight loss when combined with intensive behavioural therapy. These results established Wegovy's clinical foundation for weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities.
Mounjaro's clinical trials demonstrated different weight loss profiles due to its dual GIP and GLP-1 mechanism, though direct comparison between Wegovy and Mounjaro trial results requires caution due to different study designs, populations, and endpoints. Both medications represent evidence-based approaches to weight management, with individual response varying based on patient factors, adherence, and lifestyle modifications. The choice between Wegovy compared to Mounjaro often depends on individual clinical circumstances, monthly budget considerations, and prescriber recommendations rather than head-to-head trial comparisons.
How Wegovy's GLP-1 Mechanism Affects Monthly Value
Wegovy works as a GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates appetite and food intake after meals. This mechanism promotes feelings of fullness with smaller portions, potentially reducing food costs alongside the monthly medication expense. The appetite reduction effects may help patients achieve better portion control, reducing overall food expenditure whilst supporting weight management goals. Unlike short-term appetite suppressants, Wegovy's mechanism addresses the underlying hormonal signals that control hunger and satiety. The once-weekly injection schedule provides consistent appetite regulation throughout the week, supporting sustainable eating pattern changes. This comprehensive approach to appetite management justifies the monthly investment by addressing multiple aspects of weight regulation simultaneously.
Streamlined Ordering Process for Cost-Effective Supply
EverydayMeds ensures cost-effective Wegovy supply through a streamlined three-minute online clinical assessment, eliminating traditional pharmacy visit costs and time investments. Prescriber review typically completes within three working days (express 24-hour option available), enabling prompt treatment initiation without private consultation fees. Next-day cold-chain delivery ensures medication integrity whilst minimising travel costs to collect prescriptions from traditional pharmacies. The online service operates under GPhC registration #9012878, providing regulated pharmacy standards with enhanced convenience and transparent pricing. Bundle ordering options reduce delivery frequency and associated costs, whilst maintaining continuous medication supply throughout the dose escalation phases. This efficient process eliminates hidden costs associated with traditional prescription collection whilst ensuring clinical safety through qualified prescriber oversight.
Storage Advantages Affecting Long-Term Costs
Wegovy's superior storage flexibility compared to Mounjaro provides practical cost advantages for long-term users, particularly regarding travel and power outage scenarios. The medication tolerates up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limit, reducing replacement costs due to temperature exposure. The FlexTouch pen design ensures accurate dosing throughout the storage period, maintaining clinical effectiveness without waste due to delivery mechanism failures. This storage resilience proves particularly valuable for patients with irregular schedules, frequent travel, or unreliable refrigeration, where medication replacement costs could otherwise impact monthly budgets. The extended room temperature stability effectively provides insurance against storage-related medication loss, protecting the monthly investment in weight management treatment. Proper storage planning maximises the value of each pen throughout its intended usage period.
Long-Term Budget Planning for Wegovy Compared to Mounjaro
Effective budget planning for Wegovy compared to Mounjaro requires understanding both medications' long-term cost trajectories and maintenance requirements. Wegovy's maintenance phase at 2.4mg represents £209.99 monthly ongoing costs, whilst the escalation phase spreads £624.96 across 16 weeks, averaging £156.24 per month during dose increases. Annual maintenance costs approximate £2,520 for individual pen purchases, though bundle options and discount codes can optimise these expenses for committed users.
The financial commitment extends beyond medication costs to include clinical monitoring, dietary modifications, and lifestyle changes that support optimal outcomes. Both Wegovy compared to Mounjaro represent significant monthly investments, but the cost per percentage point of weight loss achieved often proves economically favourable compared to alternative interventions like private weight management programmes or surgical options. EverydayMeds' transparent pricing eliminates subscription fees or membership costs, allowing accurate monthly budget forecasting throughout treatment duration.
Accessing Both Options Through EverydayMeds
Both Wegovy and Mounjaro are available from EverydayMeds, ensuring patients can access either prescription-only medicine based on clinical appropriateness and budget considerations rather than supply limitations. Your prescriber can help determine which medication aligns best with your clinical profile, lifestyle requirements, and monthly budget constraints during the online assessment process. The clinical team at GPhC #9012878 ensures both options meet the same safety standards, with personalised recommendations based on individual circumstances rather than medication availability. New customers can explore both options using code FIRST40, whilst returning customers benefit from DOSE25 for continued competitive pricing regardless of their chosen medication. This comprehensive approach ensures treatment decisions focus on clinical suitability and personal preferences rather than supply constraints or pricing disparities between the two medications. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and discuss both options with qualified prescribers who can guide your choice between these effective weight management treatments.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
